LEAD ARTICLE
REVIEWS
PERINATOLOGY AND NEONATOLOGY
Objective. To estimate the impact of the complicated perinatal period on cerebral hemodynamics in high-risk neonates who have experienced hypoxia-ischemia and been born by caesarean section. Patients and methods. Structural characteristics of the brain and its hemodynamics were examined in 690 neonates born by different modes of delivery at various gestational ages (out of them 540 neonates had experienced hypoxia-ischemia).
Results. In the first 24 hours of life, the babies with a compromised perinatal period, especially after caesarean section, developed structural changes in the brain and its hemodynamic disorders that were correlated with the severity of prior hypoxia-ischemia and the degree of prematurity. The neonatal period was marked by the delayed recovery of cerebral hemodynamics in infants exposed to a set of damaging factors.
Conclusion. The complicated perinatal period and the joint impact of hypoxia-ischemia, operative delivery, and preterm pregnancy on the fetus and the neonate result in persistent impairment of cerebral blood flow. The early diagnosis of brain structural and hemodynamic disorders serves as the basis for an in-depth examination of the central nervous system and for effective drug correction in order to prevent decompensation and its related complications.
НЕФРОЛОГИЯ
НЕВРОЛОГИЯ
INFECTIOUS DISEASES
Objective: to study the intestinal microflora in children with emergencies due to enteric infections. Subjects and methods. A total of 147 patients aged 6 months to 14 years were examined. Clinical, scatological, and bacteriological studies were used.
Results. Grade III dysbacteriosis was shown to be prevalent in children with emergencies due to enteric infections.
Conclusion. Analysis of the microbial landscape of isolated pathogens revealed the dominant role of Proteus and a significant proportion of Pseudomonas aeruginosa and permanently relevant Staphylococcus aureus.
The authors give the material of their own observations on the clinical and laboratory efficacy of the Russian intravenous immunoglobulin Gabriglobin for the treatment of enteroviral meningitides in children.
The performed trials indicated that the use of Gabriglobin in the combination therapy of severe enteroviral meningitides in children reduced the duration of intoxication, global cerebral symptoms, meningeal syndrome, the time of cerebrospinal fluid sanitation by 1,5 times, and that of in-hospital treatment by 5,8±1,8 days as compared to those who received conventional basic therapy.
SPORTS MEDICINE
A comment on the article “The levels of bioelements in the saliva and hair of young athletes” by N.A. Troegubova et al.
SHARING EXPERIENCES
To reduce the damaging action of hypoxia and to correct severe metabolic and cardiac disorders in critically ill premature newborn infants, metabolic therapy with cytoflavin was studied in extremely premature infants (33 and 25 babies in a study group and a comparison one, respectively).
The use of this drug in extremely low and very low birthweight babies with posthypoxic myocardial damage and severe metabolic disorders was found to lead to normalization of acid-base balance within 24 hours after treatment initiation. During the therapy, there was a marked cardiocytoprotective effect and no increase in the degree of intragastric bleedings.
TO THE PRACTITIONER ASSISTANCE
The paper presents the clinical results of a double-blind, randomized, placebo-controlled multicenter phase III study evaluating the clinical efficacy and safety of Ingavirin® capsules 30 mg at a daily dose of 60 mg for the treatment of influenza and other acute respiratory viral infections (ARVI) in 7–12-year-old children.
The study included 310 children of both sexes. The study participants took Ingavirin® 60 mg/day or placebo for 5 days. The drug was shown to be effective in normalizing temperature and alleviating intoxication and catarrhal syndromes just at day 3 of therapy. Ingavirin® was demonstrated to considerably reduce the risk of bacterial complications of ARVI/influenza, which require antibiotic therapy, which is important for clinical use in children. This clinical trial has shown the high safety and tolerance of the drug. Ingavirin® contributes to accelerated virus elimination, shorter disease duration, and lower risk of complications.
OBITUARY
ISSN 2500-2228 (Online)